Efficacy and Safety of Denosumab Vs. Bisphosphonates in Postmenopausal Women Previously Treated with Oral Bisphosphonates

Overview

Journal Osteoporos Int

Specialties Endocrinology
Orthopedics

Date 2019 Nov 29

PMID 31776637

Citations 28

Authors

P D Miller

N Pannacciulli

J Malouf-Sierra

A Singer

E Czerwinski

H G Bone

C Wang

S Huang

A Chines

W Lems

J P Brown

Affiliations

Soon will be listed here.

Abstract

Introduction: We conducted a patient-level pooled analysis of four studies to estimate the efficacy and safety of transitioning to denosumab vs. continuing bisphosphonate treatment in postmenopausal women who previously received oral bisphosphonates.

Methods: Patients received 60 mg denosumab once every 6 months or a bisphosphonate (oral alendronate, risedronate, ibandronate, or intravenous zoledronic acid). Endpoints were change from baseline in lumbar spine, total hip, femoral neck, and 1/3 radius BMD at month 12, change from baseline in serum CTX-1 and P1NP, and incidence of adverse events.

Results: A total of 2850 randomized patients (1424 bisphosphonate:1426 denosumab) were included in the analysis. Percentage change in BMD was significantly greater (p < 0.001) for denosumab vs. bisphosphonate at each skeletal site; differences in BMD changes ranged from 0.6 to 2.0%. Percentage decrease in serum CTX-1 and P1NP was significantly greater (p < 0.0001) for denosumab vs. bisphosphonate at months 1, 6, and 12; in the denosumab group only, percentage change in serum CTX-1 at month 1 was significantly correlated with percentage change in lumbar spine and total hip BMD at month 12. The incidences of adverse events were similar between treatment groups. Three patients (one bisphosphonate and two denosumab) had atypical femoral fractures, all from the denosumab vs. zoledronic acid study.

Conclusion: Postmenopausal women can safely transition from a bisphosphonate to denosumab, which is more effective at improving BMD than continuing with a bisphosphonate.

Clinical Trials Registration: NCT00377819, NCT00919711, NCT00936897, NCT01732770.

Citing Articles

Surveillance of drug prescribing: why outliers miss their targets - a qualitative study.

Gollnick J, Zeschick N, Horbrand F, Killian P, Sebastiao M, Kuhlein T BMC Health Serv Res. 2025; 25(1):17.

PMID: 39754176 PMC: 11697825. DOI: 10.1186/s12913-024-12189-0.

Case Report: single low-dose of denosumab as a trigger of MRONJ development in a patient with osteoporosis after bisphosphonate therapy.

Szaraz D, Perina V, Treglerova J, Machacek C, Zendulka O, Borilova Linhartova P Front Oral Health. 2024; 5:1473049.

PMID: 39697786 PMC: 11652535. DOI: 10.3389/froh.2024.1473049.

Efficacy and safety of teriparatide vs. bisphosphonates and denosumab vs. bisphosphonates in osteoporosis not previously treated with bisphosphonates: a systematic review and meta-analysis of randomized controlled trials.

Li M, Ge Z, Zhang B, Sun L, Wang Z, Zou T Arch Osteoporos. 2024; 19(1):89.

PMID: 39312040 PMC: 11420281. DOI: 10.1007/s11657-024-01447-7.

The emerging role of osteoclasts in the treatment of bone metastases: rationale and recent clinical evidence.

Liu Y, Chen H, Chen T, Qiu G, Han Y Front Oncol. 2024; 14:1445025.

PMID: 39148909 PMC: 11324560. DOI: 10.3389/fonc.2024.1445025.

Denosumab vs. bisphosphonates in primary osteoporosis: a meta-analysis of comparative safety in randomized controlled trials.

Kobayashi T, Morimoto T, Ito K, Mawatari M, Shimazaki T Osteoporos Int. 2024; 35(8):1377-1393.

PMID: 38733394 DOI: 10.1007/s00198-024-07118-0.

References

Lyu H, Jundi B, Xu C, Tedeschi S, Yoshida K, Zhao S . Comparison of Denosumab and Bisphosphonates in Patients With Osteoporosis: A Meta-Analysis of Randomized Controlled Trials. J Clin Endocrinol Metab. 2018; 104(5):1753-1765. PMC: 6447951. DOI: 10.1210/jc.2018-02236. View

Rodan G, Reszka A, Golub E, Rizzoli R . Bone safety of long-term bisphosphonate treatment. Curr Med Res Opin. 2004; 20(8):1291-300. DOI: 10.1185/030079904125004475. View

Kothawala P, Badamgarav E, Ryu S, Miller R, Halbert R . Systematic review and meta-analysis of real-world adherence to drug therapy for osteoporosis. Mayo Clin Proc. 2007; 82(12):1493-501. DOI: 10.1016/S0025-6196(11)61093-8. View

Miller P, Pannacciulli N, Brown J, Czerwinski E, Nedergaard B, Bolognese M . Denosumab or Zoledronic Acid in Postmenopausal Women With Osteoporosis Previously Treated With Oral Bisphosphonates. J Clin Endocrinol Metab. 2016; 101(8):3163-70. PMC: 4971333. DOI: 10.1210/jc.2016-1801. View

Russell R . Bisphosphonates: mode of action and pharmacology. Pediatrics. 2007; 119 Suppl 2:S150-62. DOI: 10.1542/peds.2006-2023H. View

Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S . Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci U S A. 1998; 95(7):3597-602. PMC: 19881. DOI: 10.1073/pnas.95.7.3597. View

Burgess T, Qian Y, Kaufman S, Ring B, Van G, Capparelli C . The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts. J Cell Biol. 1999; 145(3):527-38. PMC: 2185088. DOI: 10.1083/jcb.145.3.527. View

Udagawa N, Takahashi N, Yasuda H, Mizuno A, Itoh K, Ueno Y . Osteoprotegerin produced by osteoblasts is an important regulator in osteoclast development and function. Endocrinology. 2000; 141(9):3478-84. DOI: 10.1210/endo.141.9.7634. View

Kendler D, Roux C, Benhamou C, Brown J, Lillestol M, Siddhanti S . Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy. J Bone Miner Res. 2009; 25(1):72-81. DOI: 10.1359/jbmr.090716. View

10.

Wu J, Zhang Q, Yan G, Jin X . Denosumab compared to bisphosphonates to treat postmenopausal osteoporosis: a meta-analysis. J Orthop Surg Res. 2018; 13(1):194. PMC: 6090940. DOI: 10.1186/s13018-018-0865-3. View

11.

Caro J, Ishak K, Huybrechts K, Raggio G, Naujoks C . The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporos Int. 2004; 15(12):1003-8. DOI: 10.1007/s00198-004-1652-z. View

12.

Shane E, Burr D, Abrahamsen B, Adler R, Brown T, Cheung A . Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2013; 29(1):1-23. DOI: 10.1002/jbmr.1998. View

13.

Black D, Delmas P, Eastell R, Reid I, Boonen S, Cauley J . Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007; 356(18):1809-22. DOI: 10.1056/NEJMoa067312. View

14.

Imel E, Eckert G, Modi A, Li Z, Martin J, de Papp A . Proportion of osteoporotic women remaining at risk for fracture despite adherence to oral bisphosphonates. Bone. 2015; 83:267-275. DOI: 10.1016/j.bone.2015.11.021. View

15.

Roux C, Hofbauer L, Ho P, Wark J, Zillikens M, Fahrleitner-Pammer A . Denosumab compared with risedronate in postmenopausal women suboptimally adherent to alendronate therapy: efficacy and safety results from a randomized open-label study. Bone. 2013; 58:48-54. DOI: 10.1016/j.bone.2013.10.006. View

16.

Cramer J, Amonkar M, Hebborn A, Altman R . Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. Curr Med Res Opin. 2005; 21(9):1453-60. DOI: 10.1185/030079905X61875. View

17.

Siris E, Harris S, Rosen C, Barr C, Arvesen J, Abbott T . Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc. 2006; 81(8):1013-22. DOI: 10.4065/81.8.1013. View

18.

Lacey D, Tan H, Lu J, Kaufman S, Van G, Qiu W . Osteoprotegerin ligand modulates murine osteoclast survival in vitro and in vivo. Am J Pathol. 2000; 157(2):435-48. PMC: 1850124. DOI: 10.1016/S0002-9440(10)64556-7. View

19.

Gold D, Martin B, Frytak J, Amonkar M, Cosman F . A claims database analysis of persistence with alendronate therapy and fracture risk in post-menopausal women with osteoporosis. Curr Med Res Opin. 2007; 23(3):585-94. DOI: 10.1185/030079906X167615. View

20.

Byun J, Jang S, Lee S, Park S, Yoon H, Yoon B . The Efficacy of Bisphosphonates for Prevention of Osteoporotic Fracture: An Update Meta-analysis. J Bone Metab. 2017; 24(1):37-49. PMC: 5357611. DOI: 10.11005/jbm.2017.24.1.37. View